Dexamethasone Suppressed LPS-Induced Matrix Metalloproteinase and Its Effect on Endothelial Glycocalyx Shedding

Mediators of Inflammation

Volumn 2015, Issue , 2015, Pages

  Cui, Na ^a   Wang, Hao ^a   Long, Yun ^a   Su, Longxiang ^a   Liu, Dawei ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DOXYCYCLINE; GELATINASE A; GELATINASE B; LIPOPOLYSACCHARIDE; PROTEIN ZO1; SYNDECAN 1; MATRIX METALLOPROTEINASE; TJP1 PROTEIN, RAT;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GLYCOCALYX; HOMOGENATE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LIPOPOLYSACCHARIDE-INDUCED ENDOTOXEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; RAT; SEPSIS; THORACIC AORTA; UPREGULATION; VASCULAR ENDOTHELIUM; ANIMAL; AORTA; CYTOLOGY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; METABOLISM;

ANIMALIA; ESCHERICHIA COLI; RATTUS;

ANIMALS; AORTA; DEXAMETHASONE; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOCALYX; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; RATS; SYNDECAN-1; ZONULA OCCLUDENS-1 PROTEIN;

EID: 84936817304     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2015/912726     Document Type: Article

References (26)

1. E. L. V. Costa, I. A. L. Schettino, andG. P. P. Schettino, "Thelung in sepsis: guilty or innocent?" Endocrine, Metabolic and Immune Disorders-Drug Targets, vol. 6, no. 2, pp. 213-216, 2006.
2. S. M. Hollenberg, M. Guglielmi, and J. E. Parrillo, "Discordance between microvascular permeability and leukocyte dynamics in septic inducible nitric oxide synthase deficient mice, " Critical Care, vol. 11, no. 6, article R125, 2007.
3. A. Harrois, O. Huet, and J. Duranteau, "Alterations ofmitochondrial function in sepsis and critical illness, " Current Opinion in Anaesthesiology, vol. 22, no. 2, pp. 143-149, 2009.
4. W. C. Parks, C. L. Wilson, and Y. S. López-Boado, "Matrix metalloproteinases as modulators of inflammation and innate immunity, " Nature Reviews Immunology, vol. 4, no. 8, pp. 617-629, 2004.
5. H. Wiig, "Pathophysiology of tissue fluid accumulation in inflammation, " Journal of Physiology, vol. 589, no. 12, pp. 2945-2953, 2011.
6. D. Chappell, M. Jacob, K. Hofmann-Kiefer, P. Conzen, and M. Rehm, "A rational approach to perioperative fluid management, " Anesthesiology, vol. 109, no. 4, pp. 723-740, 2008.
7. A. Donati, D. Tibboel, and C. Ince, "Towards integrative physiological monitoring of the critically ill: from cardiovascular to microcirculatory and cellular function monitoring at the bedside, " Critical Care, vol. 17, supplement 1, article S5, 2013.
8. Y. Komarova and A. B. Malik, "Regulation of endothelial permeability via paracellular and transcellular transport pathways, " Annual Review of Physiology, vol. 72, pp. 463-493, 2009.
9. D. Chappell, M. Westphal, and M. Jacob, "The impact of the glycocalyx on microcirculatory oxygen distribution in critical illness, " Current Opinion in Anaesthesiology, vol. 22, no. 2, pp. 155-162, 2009.
10. C. R. Parish, "The role of heparan sulphate in inflammation, " Nature Reviews Immunology, vol. 6, no. 9, pp. 633-643, 2006.
11. M. W. Roomi, T. Kalinovsky, J. Monterrey, M. Rath, and A. Niedzwiecki, "In vitro modulation of MMP-2 and MMP-9 in adult human sarcoma cell lines by cytokines, inducers and inhibitors, " International Journal of Oncology, vol. 43, no. 6, pp. 1787-1798, 2013.
12. M. W. Roomi, J. C. Monterrey, T. Kalinovsky, A. Niedzwiecki, andM. Rath, "Modulation ofMMP-2 andMMP-9 by cytokines, mitogens and inhibitors in lung cancer andmalignantmesothelioma cell lines, " Oncology Reports, vol. 22, no. 6, pp. 1283-1291, 2009.
13. M. M. Castro, A. D. Kandasamy, N. Youssef, and R. Schulz, "Matrix metalloproteinase inhibitor properties of tetracyclines: therapeutic potential in cardiovascular diseases, " Pharmacological Research, vol. 64, no. 6, pp. 551-560, 2011.
14. J. Xu, G.-M. Kim, S. H. Ahmed et al., "Glucocorticoid receptormediated suppression of activator protein-1 activation and matrix metalloproteinase expression after spinal cord injury, " Journal of Neuroscience, vol. 21, no. 1, pp. 92-97, 2001.
15. J. J. Cena, M. M. Lalu, W. J. Cho et al., "Inhibition ofmatrixmetalloproteinase activity in vivo protects against vascular hyporeactivity in endotoxemia, " The American Journal of Physiology-Heart and Circulatory Physiology, vol. 298, no. 1, pp. H45-H51, 2010.
16. M. M. Lalu, T. Csont, and R. Schulz, "Matrix metalloproteinase activities are altered in the heart and plasma during endotoxemia, " Critical CareMedicine, vol. 32, no. 6, pp. 1332-1337, 2004.
17. A. Nelson, I. Berkestedt, A. Schmidtchen, L. Ljunggren, and M. Bodelsson, "Increased levels of glycosaminoglycans during septic shock: relation to mortality and the antibacterial actions of plasma, " Shock, vol. 30, no. 6, pp. 623-627, 2008.
18. N. V. Bogatcheva and A. D. Verin, "The role of cytoskeleton in the regulation of vascular endothelial barrier function, " Microvascular Research, vol. 76, no. 3, pp. 202-207, 2008.
19. J. G. N. Garcia, "Concepts in microvascular endothelial barrier regulation in health and disease, " Microvascular Research, vol. 77, no. 1, pp. 1-3, 2009.
20. C. E. Brinckerhoff and L. M. Matrisian, "Matrix metalloproteinases: a tail of a frog that became a prince, " Nature Reviews Molecular Cell Biology, vol. 3, no. 3, pp. 207-214, 2002.
21. A. Page-McCaw, A. J. Ewald, and Z. Werb, "Matrix metalloproteinases and the regulation of tissue remodelling, " Nature Reviews Molecular Cell Biology, vol. 8, no. 3, pp. 221-233, 2007.
22. M. M. Castro, J. E. Tanus-Santos, and R. F. Gerlach, "Matrix metalloproteinases: targets for doxycycline to prevent the vascular alterations of hypertension, " Pharmacological Research, vol. 64, no. 6, pp. 567-572, 2011.
23. D. Chappell, K. Hofmann-Kiefer, M. Jacob et al., "TNF- induced shedding of the endothelial glycocalyx is prevented by hydrocortisone and antithrombin, " Basic Research in Cardiology, vol. 104, no. 1, pp. 78-89, 2009.
24. D. Chappell, M. Jacob, K. Hofmann-Kiefer et al., "Hydrocortisone preserves the vascular barrier by protecting the endothelial glycocalyx, " Anesthesiology, vol. 107, no. 5, pp. 776-784, 2007.
25. C. Forster, C. Silwedel, N. Golenhofen et al., "Occludin as direct target for glucocorticoid-induced improvement of bloodbrain barrier properties in a murine in vitro system, " Journal of Physiology, vol. 565, no. 2, pp. 475-486, 2005.
26. I. A. Romero, K. Radewicz, E. Jubin et al., "Changes in cytoskeletal and tight junctional proteins correlate with decreased permeability induced by dexamethasone in cultured rat brain endothelial cells, " Neuroscience Letters, vol. 344, no. 2, pp. 112-116, 2003.